scholarly journals Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital

2010 ◽  
Vol 45 (8) ◽  
pp. 1274-1280 ◽  
Author(s):  
I Ilari ◽  
M A De Ioris ◽  
G M Milano ◽  
R Pessolano ◽  
C De Lurentis ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Children's Hospital ◽  
Children’S Hospital

High dose chemotherapy with peripheral blood stem cell (P.B.S.C.) rescue in metastatic Ewing’s sarcoma at diagnosis

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 9004-9004
Author(s):  
A. Tienghi ◽  
S. Ferrari ◽  
M. Mercuri ◽  
P. Giovanis ◽  
E. Barbieri ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Peripheral Blood Stem Cell ◽  
High Dose Chemotherapy ◽  
Blood Stem Cell ◽  
High Dose

1202 High-dose chemotherapy (HDC) with stemcell rescue for patients with metastatic Ewing's sarcoma

1995 ◽  
Vol 31 ◽  
pp. S251
Author(s):  
M.A. Nooy ◽  
W. Fibbe ◽  
J. Ouwerkerk ◽  
D. van Benthem ◽  
E.M. Noordijk
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
High Dose Chemotherapy ◽  
High Dose

scholarly journals High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre

Sarcoma ◽  
2004 ◽  
Vol 8 (2-3) ◽  
pp. 63-69 ◽  
Author(s):  
Sébastien J. Hotte ◽  
Anne M. Smith ◽  
Vivien H.C. Bramwell ◽  
Kang Howson-Jan
Keyword(s):  
Stem Cell ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Residual Disease ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Cell Transplant ◽  
Alive With Disease ◽  
Risk Patients ◽  
Time To Relapse

Purpose: Few reports have been published on the evaluation of stem cell auto transplantation for chemosensitive sarcomas. Some suggest benefit, others do not. We present results of 24 patients with sarcoma undergoing autotransplantation at a Canadian institution.Patients and Methods: Twenty-four patients were treated between 1988 and 1998: 23 were ≥18 years (median 27; range 12–56); genders were equal; 12 patients had Ewing's sarcoma. At diagnosis, 12 (50%) had metastatic disease. Prior to autotransplant, all had ≥1 chemotherapy regimen. Fourteen (58%) were in complete remission (CR) and seven (29%) had minimal residual disease. All received etoposide 60 mg/kg (Day –4), melphalan 140 mg/m2on (Day –3) and a stem cell reinfusion (Day 0).Results: Three patients (12.5%) were alive and disease-free with median follow-up of 92 months (80–142); one was alive with disease 32 months post-autotransplant. Twenty had died (disease, 17; transplant-related, 2; unknown, 1). Of the four alive, three had Ewing's sarcoma, one alveolar rhabdomyosarcoma, and all were in CR at transplant. Median time to relapse was 6 months (2–59). Sixteen of 18 (89%) relapsed within 1 year. Median overall survival was 10 months (0–137). A trend towards improved survival (P=0.07) was evident for patients in CR prior to autotransplant.Conclusions: Stem cell autotransplantation does not benefit most patients with sarcoma. A subgroup of high-risk patients in CR may fare better and warrant further study.

scholarly journals Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy

Sarcoma ◽  
2008 ◽  
Vol 2008 ◽  
pp. 1-4 ◽  
Author(s):  
J. Thariat ◽  
A. Italiano ◽  
F. Peyrade ◽  
I. Birtwisle-Peyrottes ◽  
L. Gastaud ◽  
...  
Keyword(s):  
Multimodal Therapy ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
High Dose Chemotherapy ◽  
Local Relapse ◽  
High Dose ◽  
Curative Intent ◽  
First Occurrence ◽  
History Of ◽  
Left Maxillary Sinus

Ewing's sarcoma's relapse rarely occurs more than two years after the initial diagnosis. We report the case of a 26-year-old man with a history of Ewing's sarcoma of the left maxillary sinus at the age of 10 who presented with a very late local relapse, 16 years after the first occurrence of disease. Ultimate control was achieved after multimodal therapy including surgery, high-dose chemotherapy, and radiotherapy. This report indicates that local relapses of Ewing's sarcoma can be treated with curative intent in selected cases.

scholarly journals Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma: A Systematic Review

Sarcoma ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Pavan Tenneti ◽  
Umar Zahid ◽  
Ahmad Iftikhar ◽  
Seongseok Yun ◽  
Atif Sohail ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Final Analysis ◽  
The United States ◽  
High Dose Chemotherapy ◽  
Systemic Review ◽  
High Dose ◽  
Randomized Controlled Studies

Background. Relapsed Ewing’s sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival benefits, it is not generally used in the United States for RES. We performed a systemic review to evaluate the benefits of HDCT for RES. Methods. Literature search involved Medline, Embase, and Cochrane database. We included studies with RES patients treated with HDCT/ASCT. Results. Twenty-four studies with total of 345 reported RES patients that got HDCT were included in final analysis. Seventeen studies had patients with multiple malignancies including RES, while seven had only RES patients. At 2 and 3–5 years, event-free survival (EFS) in studies with only RES patients ranged 42–47% and 20–61% and overall survival (OS) ranged 50–66% and 33–77%, respectively. In studies with combined patients that reported outcomes of RES separately, the EFS at 1–3 and 4 years was 36–66% and 17–50%, respectively. The OS at 1-2 and 3-4 years was 40–60% and 50–70%. Conclusions. Most studies using HDCT/ASCT as consolidation regimen showed improved survival benefits compared to CC. Randomized controlled studies are needed to determine true clinical benefits of HDCT followed by ASCT in patients with RES.

High-dose chemotherapy with autologous stem cell transplantation for relapsed Ewing's sarcoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 10545-10545
Author(s):  
E. Palmerini ◽  
A. Brach Del Prever ◽  
F. Fagioli ◽  
R. Luksch ◽  
A. Prete ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Lung Metastases ◽  
Standard Dose ◽  
High Dose Chemotherapy ◽  
High Dose

10545 Background: Nearly 30–40% of patients with newly diagnosed, non-metastatic Ewing's Sarcoma (EWS) relapse. Post-relapse survival (PRS) in EWS is very poor, with less than 15–20% alive 5-years after recurrence. The role of high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is under investigation in metastatic and high risk localized EWS patients. In order to improve PRS, we employed HDCT with ASCT in EWS patients at 1st relapse. Methods: All non-metastatic EWS patients treated in Italian Sarcoma Group centers who relapsed between 1999 and June 2008 were offered HDCT (busulfan 4 mg/kg × 4 days orally and melphalan 140 mg/m2) with ASCT whenever possible (no previous HDCT; stable or responding disease after standard dose chemotherapy; adequate peripheral blood stem cells harvest). Results: 72 EWS patients experienced disease recurrence. Fifty (62%) were male. Twenty-eight (39%) of patients had previously received HDCT. Median relapse free interval (RFI) was 16 months (2.8–64). Pattern of relapse was: lung metastases in 20 (28%) patients, bone metastases in 12 (16%), local recurrence in 11 (15%) and multiple sites in 29 (40%). Treatment at 1st relapse was: standard dose chemotherapy in 31 (43%) patients; HDCT followed by ASCT in 24 (33%); palliative treatment in 12 (17%) and surgery only in 5 (7%). Three patients died of treatment-related toxicity. With a median follow-up of 24 months (1–64), the 3-year post-relapse survival (PRS) was 21% (95%CI 7–35). 3-year PRS was better for patients with a lung only relapse [48%, (95%CI 21–74)] and a RFI > 2 years [51%, (95%CI 27–76)]. 3-year PRS was 33% (95%CI 13–54) for patients treated with HDCT and 22% (95%CI 6–39) for those receiving standard dose chemotherapy. A significant (P 0.02) advantage was observed in the subgroup of patients with a shorter RFI treated with HDCT [3-year PRS 29% (95%CI 5–52)] compared to those treated with standard dose chemotherapy [3-years PRS 13%, (95%CI 2–29)]. Conclusions: Pattern of recurrence and RFI are the main factors influencing PRS in EWS. The use of HDCT with ASCT in recurrent EWS is investigational. Patients with shorter RFI could more likely benefit from HDCT. No significant financial relationships to disclose.

Ewing's sarcoma of the mandible: a combined approach to treatment

2002 ◽  
Vol 26 (4) ◽  
pp. 409-412 ◽  
Author(s):  
Allen Fred Fielding ◽  
Rochelle Lindemeyer ◽  
Julie Wood-Harris ◽  
Michael Hartman
Keyword(s):  
Malignant Tumor ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Long Bones ◽  
Incisional Biopsy ◽  
Combined Approach ◽  
Children's Hospital ◽  
Children’S Hospital ◽  
The Face ◽  
Caucasian Female

Ewing's Sarcoma (ES) is a malignant tumor, which arises primarily in children. Most commonly found in the long bones and pelvis, it rarely is found in the bones of the face. This is a report of ES of the mandible in a nine-year-old Caucasian female. Treatment for this malignancy included an incisional biopsy, chemotherapy and radiotherapy protocol to the involved area in accordance with St. Christopher's Hospital and the Children's Hospital of Philadelphia. The patient is currently diseasefree and has been for approximately five years.

Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing’s sarcoma family of tumors

2012 ◽  
Vol 18 (6) ◽  
pp. 1114-1118 ◽  
Author(s):  
Shintaro Iwata ◽  
Tsukasa Yonemoto ◽  
Takeshi Ishii ◽  
Kyoya Kumagai ◽  
Reiko Imai ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
High Dose Chemotherapy ◽  
Carbon Ion Radiotherapy ◽  
High Dose ◽  
Carbon Ion
Sign in / Sign up

Export Citation Format

Share Document